0.4701
price down icon10.29%   -0.0539
after-market Handel nachbörslich: .48 0.0099 +2.11%
loading
Schlusskurs vom Vortag:
$0.524
Offen:
$0.5
24-Stunden-Volumen:
614.74K
Relative Volume:
0.47
Marktkapitalisierung:
$76.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-41.23M
KGV:
-0.6716
EPS:
-0.7
Netto-Cashflow:
$-11.54M
1W Leistung:
-27.62%
1M Leistung:
-47.40%
6M Leistung:
-6.37%
1J Leistung:
-83.03%
1-Tages-Spanne:
Value
$0.4619
$0.52
1-Wochen-Bereich:
Value
$0.4619
$0.635
52-Wochen-Spanne:
Value
$0.395
$2.97

Renovaro Inc Stock (RENB) Company Profile

Name
Firmenname
Renovaro Inc
Name
Telefon
45 39179840
Name
Adresse
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
RENB's Discussions on Twitter

Vergleichen Sie RENB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RENB
Renovaro Inc
0.4701 76.34M 0 -41.23M -11.54M -0.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Renovaro Inc Aktie (RENB) Neueste Nachrichten

pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Buys 163,160 Shares of Renovaro Inc. (NASDAQ:RENB) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Predictive Oncology pushing forward with Renovaro merger despite $10.8M loss in 2024 - The Business Journals

Apr 01, 2025
pulisher
Apr 01, 2025

Predictive Oncology Advances AI Merger Plans Despite $10.8M Loss: Key Strategic Moves Revealed - Stock Titan

Apr 01, 2025
pulisher
Mar 30, 2025

Bank of New York Mellon Corp Grows Stake in Renovaro Inc. (NASDAQ:RENB) - Defense World

Mar 30, 2025
pulisher
Mar 21, 2025

PawTides.com Partners with Rescue 22 Foundation to Support Veterans and Rescue Dogs - openPR

Mar 21, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Acquires 62,204 Shares of Renovaro Inc. (NASDAQ:RENB) - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

New York State Common Retirement Fund Trims Stake in Renovaro Inc. (NASDAQ:RENB) - Defense World

Mar 07, 2025
pulisher
Mar 04, 2025

Predictive Oncology receives financing from Renovaro Biosciences - Pennsylvania Business Report -

Mar 04, 2025
pulisher
Mar 04, 2025

Renovaro (RENB) and Predictive Oncology Partner for AI-Driven Drug Discovery: What’s Next for Cancer and HIV Treatments? - Yahoo Finance

Mar 04, 2025
pulisher
Mar 03, 2025

Sea (SE) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail

Mar 03, 2025
pulisher
Mar 03, 2025

Renovaro provides financing to Predictive Oncology as both move to finalize definitive merger agreement - The Business Journals

Mar 03, 2025
pulisher
Mar 03, 2025

MarketsMedicine Hat News - Financial Content

Mar 03, 2025
pulisher
Mar 03, 2025

Milestone Merger Payment made with Predictive Oncology to Advance AI-Driven Biomarker Discovery and Precision Medicine in Cancer and Beyond: Renovaro, Inc. (NASDAQ: RENB) - The Globe and Mail

Mar 03, 2025
pulisher
Mar 03, 2025

What To Expect From Best Buy’s (BBY) Q4 Earnings - The Globe and Mail

Mar 03, 2025
pulisher
Mar 03, 2025

Milestone Merger Payment made with Predictive Oncology - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

Renovaro Completes First Milestone Payment To Finalize Definitive Agreement With Predictive Oncology - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Predictive Oncology Moves To Finalize Definitive Merger Agreement With Renovaro Biosciences - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Renovaro Biosciences Advances Financing for AI-Driven Integration and Strategic Expansion in Oncology through Acquisition of Predictive Oncology - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Can Renovaro's AI Oncology Merger Unlock Value From 150,000+ Tumor Samples? - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Can This AI-Powered Oncology Merger Transform Cancer Treatment? First Financing Milestone Reached - StockTitan

Mar 03, 2025
pulisher
Feb 28, 2025

Renovaro Stock Price, Quotes and Forecasts | NASDAQ:RENB - Benzinga

Feb 28, 2025
pulisher
Feb 28, 2025

Renovaro Biosciences Announces Merger with BioSymetrics - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Rocket Lab Stock Is Down 30% in the Last Month. Should You Buy the Dip or Run Far Away? - The Globe and Mail

Feb 28, 2025
pulisher
Feb 28, 2025

Renovaro announces $15 million in equity - MSN

Feb 28, 2025
pulisher
Feb 27, 2025

Renovaro Inc. (RENB) Merges with BioSymetrics to Advance AI-Driven Cancer Research - Insider Monkey

Feb 27, 2025
pulisher
Feb 26, 2025

Renovaro Announces $15 million in Equity Committed - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Renovaro secures $15 million for cancer AI technology By Investing.com - Investing.com Australia

Feb 26, 2025
pulisher
Feb 26, 2025

Enochian Biosciences Stock: AI-Powered Merger Fuels Growth - sharewise

Feb 26, 2025
pulisher
Feb 26, 2025

Sector Update: Health Care -February 26, 2025 at 03:37 pm EST - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Merger Agreement with BioSymetrics to Accelerate Biomarker Identification, Enhance Drug Discovery and Expand Precision Medicine Applications in Advanced Cancer Diagnosis and Treatment | FinancialContent Business Page - Financial Content

Feb 26, 2025
pulisher
Feb 26, 2025

Renovaro and BioSymetrics merge to boost AI-driven drug discovery - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

Renovaro and BioSymetrics merge to boost AI-driven drug discovery By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

$15 Million in New Equity to Support Advanced Cancer Diagnostics, Personalized Immunotherapy, Treatments & Drug Discovery: Renovaro Stock Symbol: RENB - WICZ

Feb 26, 2025
pulisher
Feb 26, 2025

Renovaro Agrees to Merge With BioSymetrics -February 26, 2025 at 01:47 pm EST - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Renovaro & Biosymetrics Announce Definitive Merger Agreement -February 26, 2025 at 01:27 pm EST - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Renovaro and BioSymetrics Announce Definitive Merger - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and - EIN News

Feb 26, 2025
pulisher
Feb 26, 2025

Renovaro Gets $15 Million in Equity Committed; Shares Rise -February 26, 2025 at 10:58 am EST - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Renovaro secures $15 million for cancer AI technology - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

Renovaro Inc. Secures $15 Million in Additional Equity to Advance Cancer Diagnostics and Therapeutics - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Can $15M in Fresh Funding Help Renovaro Transform Cancer Treatment with AI? - StockTitan

Feb 26, 2025
pulisher
Feb 20, 2025

Renovaro (NASDAQ:RENB) Posts Earnings Results - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

Investors Eye Biotech Sector as Cancer Therapy Market Surges - KamloopsBCNow

Feb 20, 2025
pulisher
Feb 20, 2025

Renovaro: Fiscal Q2 Earnings Snapshot - CTPost

Feb 20, 2025

Finanzdaten der Renovaro Inc-Aktie (RENB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):